Entry and Patents: Evidence from the US Cardiovascular Pharmaceutical Sector
The goal of this study is to analyze the impact of innovation on entry, that is, the launch of a new product, for some specific three digit cardiovascular sector in the US pharmaceutical market, for the period 1988-1998. We have a panel data obtained by crossing-check IMS Health Data on sales with data on patents for companies selling products into those submarkets. We estimate a logit panel model by controlling for endogeneity, adopting submarket and firm specific variables. Our results show that own patents don’t clearly encourage entry, while patent holdings by incumbents have contrasting effects: on one hand the initial stock act as a barrier to entry, on the other hand they promote entry through the opening of new technological opportunities.
|Date of creation:||28 Apr 2017|
|Contact details of provider:|| Postal: Via Conservatorio 7, I-20122 Milan - Italy|
Phone: +39 02 50321522
Fax: +39 02 50321505
Web page: http://www.demm.unimi.it
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:mil:wpdepa:2017-07. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (DEMM Working Papers)
If references are entirely missing, you can add them using this form.